

PATENT Attorney Docket No. MRK-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Cardy et al.

CONFIRMATION NO.: 5220

SERIAL NO.:

08/737,457

GROUP NO.:

1644

FILING DATE:

May 15, 1995

EXAMINER:

Ewoldt, G.R.

TITLE:

Improvements in or Relating to Peptide Delivery

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF PAPER COPY AND/OR COMPUTER READABLE COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

Sir:		•
1.	\boxtimes	This replies to the Office communication dated <u>January 13, 2003</u> .
		A copy of the Office communication is enclosed.
2.	Subn	nitted herewith is/are (check each item as applicable)
	A.	a paper copy of the Sequence Listing for this application with each sequence assigned a separate identifier; and
	В.	a CD of the Sequence Listing for this application with each sequence assigned a separate identifier; and
	C.	a copy, in computer readable form, of the Sequence Listing for this application.

Applicants respectfully request entry of the Sequence Listing, which is provided in both paper and computer-readable form in the above-identified application. The Sequence Listing submitted herewith is intended to replace the Sequence Listing currently on file in this application.

Submission Of Paper Copy And/Or Computer Readable Copy Of Sequence Listing For Invention Containing Nucleotide And/Or Amino Acid Sequence For invention Containing Nucleonial No. 08/737,457
Attorney Docket No. MRK-003
age 2 of 2

3.

STATEMENT

3.	I here	by state	that:					
•	1 11010	of state		le items A, B and/or C)				
	A.		he contents of the paper and the are the same; and	e paper and computer readable copy submitted nd				
	В.	_	he content of the CD and same; and	ntent of the CD and computer readable copy submitted herewith ; and				
	c. the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on pages to of the original specification as filed; and							
	no new matter.							
				Respectfully submitted,				
Reg	g. No. 4	y 9, 2004 48,645 (617) 24 (617) 24	8-7697	Brian A. Fairchild, Ph.D. Attorney for Applicants Testa, Hurwitz, & Thibeault, LLP High Street Tower 125 High Street Boston, Massachusetts 02110				

07/12/04

Express Mail Mailing Label No. EV289510612US

29

	IFE.	Application	Serial Number		8/737,457	
		Filing Date	Filing Date		May 15, 1995	
f in a	احر المن المن المن المن المن المن المن المن	First Named	Inventor	Ca	ardy	
TDANGNATT	9 200, E) AL	Group Art U	Jnit	16	544 DECEMBED	
TRANSMITT	AL	Examiner N	ame	Ev	woldt, G.R.	
FORM	المعتمد والماطلة	Attorney Do	ocket No.	М	RK-003 JUL 1 6 2004	
		Patent No.		N	ot applicable	
		Issue Date		No	ot applicable	
	ENI		hack all that apply			
	EN		heck all that apply) e to File Missing		Notice of Appeal to Board	
		Parts of Applie			of Patent Appeals and Interferences	
☐ Check Attached☐ Copy of Fee Transmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)	
Amendment/Response		Request For C Examination (Status Inquiry	
☐ Preliminary ☐ After Final		Transmittal Power of Attorney (Revocation of Prior Powers)		\boxtimes	Return Receipt Postcard	
☐ Affidavits/declaration(s) ☐ Letter to Official ☐ Draftsperson					Certificate of First Class Mailing under 37 C.F.R. 1.8	
including Drawings [Total Sheets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8	
Petition for Extension of Time			aration and Power r Utility or Design	⊠	Additional Enclosure(s) (please identify below)	
		T decide 1 approve		i	Notification Regarding Change in Status	
Information Disclosure Statement (2 pages)		Small Entity S	tatement		Status	
Form PTO-1449 Copies of IDS Citations (CD(s) for large	e table or computer			
Certified Copy of Priority		Amendment A	After Allowance	07	7/15/2004 KKEMP1 00000003 08737457	
Document(s) Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above		Request for Certificate of Correction Certificate of Correction (in duplicate)			FC:1461 1955.00 (
CORRESPONDENCE ADDRESS			SIGNATURE BLO	OCK		
Testa, High S 125 Hi Bostor Tel. No	Administrator Hurwitz & Th treet Tower gh Street , MA 02110 (617) 248-7	ibeault, LLP	Date: July 9, 2004 Reg. No. 48,645 Tel. No.: (617) 248- Fax No.: (617) 248-		Respectfully submitted, Brian A. Fairchild, Ph.D. Attorney for the Applicants Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110	

Express Mail Mailing Label No. EV289510612US

		Complete if Known				
FOR A NICH HICKAY		Application Serial Number 08/737,457				
FEËTRANSMITTAL	Filing Date		T	May 15, 1995		
/ FX 2004	First Named Inventor		-	Cardy STOP HILL AT 11 20		
[2]	THSCINA	inca inventor		204 JUL 14 AN 11	: 30	
E JAIL 0 9 2004 E	Group A			1644		
	Examine			Ewoldt, G.R.		
E. G	Attorney	Docket No.		MRK-003		
METHOD OF PAYMENT			FE	E CALCULATION (continued)		
1. Payment Enclosed:		3. ADDIT	IONAL I	FEES		
Check Money Order Other		Large	Small	JUL 1 6 2004		
		Entity	Entity	00L 1		
2. The Commissioner is hereby authorized to cre		Fee	Fee	Fee Description	Fee Paid	
or charge any fee indicated below for this sub	nission	(\$)	(\$)	OFFICE OF PETTION'S		
to Deposit Account No. 20-0531.	(hor	130	65	Surphoras late filing for or oath		
Required Fees (copy of this sheet enclose		50	25		**	
Additional fee required under 37 CFR 1 1.17.	. to and	30	23	Surcharge - late provisional filing fee or cover sheet		
Overpayment Credit.		130	130			
3. Applicant claims small entity status.		2,520	2,520			
FEE CALCULATION		110	2,320	·		
1. FILING FEE		420	210			
1. LIBING PEE		720	210	month		
Large Entity		950	475	Extension for reply within third month		
	Fee Paid	1480	740	Extension for reply within fourth		
				month		
_		2010	1005	Extension for reply within fifth month		
770 Utility filing fee		330	165	••		
340 Design filing fee		330	165	Filing a brief in support of an appeal		
160 Provisional filing fee		290	145	Request for oral hearing		
		130	130			
Number Number Rate	Amount	180	180	Submission of Information Disclosure Statement		
Filed Extra	Aillouit	770	385	land the second		
Thou Lau		'''	303	rejection (37 CFR 1.129(a))		
Total Claims = x \$ 18.00 =		770	385	For each additional invention to be	-	
<i>A </i>				examined (37 CFR 1.129(b))		
Independent		100	100	Certificate of Correction for		
Claims = $x \$ 86.00 =$				applicant's error		
Multiple Dependent Claim(s), if any \$290.00 =		Other fee (Spe	cify)	* *	1955.00	
		in Notification Regarding Change in Status				
				Status		
TOTAL:						
SMALL ENTITY DISCOUNT:						
	0.00					
2. AMENDMENT CLAIM FEES	E. B.			arramam : - (a)	1055.00	
Claims Highest No. Present Rate Remaining Previously Extra	Fee Paid			SUBTOTAL (3) (\$)	1955.00	
Total - = x \$ 18.00 =				SUBTOTAL (1)	0.00	
Indep = x \$ 86.00 =				` ′ ⊨	0.00	
First Presentation of Multiple Dep. + \$290.00 =		:			1955.00	
Claim				(,)		
TOTAL:				_		
SMALL ENTITY DISCOUNT:		1				
SUBTOTAL (2)	\$)0.00	Į		TOTAL (\$)	1955.00	
CORRESPONDENCE ADDRESS		SIGNATURE BLOCK				
Direct all correspondence to:				Respectfully submitted		
Patent Administrator			•••	12. 1. (1)		
Testa, Hurwitz & Thibeault, LL	Date: July 9, 2	2004	In most	-		
High Street Tower-125 High St	Reg. No.: 48,	645	Brian A. Fairchild, Ph.D.			
Boston, MA 02110	Tel. No.: (617) 248-7697 Attorney for the Applicants					
Tel. No.: (617) 248-7000	Fax No.: (617) 248-7100 Testa, Hurwitz & Thibeault, LLP					
Fax No.: (617) 248-7100				High Street Tower-125 High S	Street	
				Boston, MA 02110		



DIVISION Express Mail Mailing Label.: EV289510612US

#50

PATENT Atty. Docket No. MRK-003

2004 JUL 14 AM 11: 30

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Cardy et al.

CONF. NO.

5220

SERIAL NO.:

08/737,457

GROUP NO.:

1644

JUL 1 6 2004

FILING DATE:

May 15, 1995

EXAMINER:

Ewoldt, G.R.OFFICE OF PETITIONS

TITLE:

IMPROVEMENTS IN OR RELATING TO PEPTIDE

DELIVERY

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

NOTIFICATION REGARDING CHANGE IN STATUS

Sir:

Pursuant to 37 C.F.R. § 1.27(g)(2), Applicants notify the U.S. Patent and Trademark Office (USPTO) that status as a small entity is no longer appropriate for the above-identified patent application.

Through error, the USPTO was not notified of a loss of entitlement to small entity status in May of 2001. Applicants request that this error be excused under 37 C.F.R. § 1.28(c). Applicants submit herewith a check in the amount of \$1955.00 for payment of the total deficiency payment owed as itemized below in accordance with 37 C.F.R. § 1.28(c)(2). Applicants believe that no other fees are due with this submission.

Nevertheless, please charge any other required fees to Deposit Account No. 20-0531.

Type of Fee	Fee Paid & Date Paid	Current Fee Amount	Deficiency
	(Small Entity Amount)	(Non-Small Entity)	(Amount Owed)
Basic Filing Fee	\$345.00 on May 25, 2001	\$770.00	\$425.00
Excess Total Claims	\$18.00 on May 25, 2001	\$36.00	\$18.00
Fee (2 extra)			
Excess Independent	\$80.00 on May 25, 2001	\$172.00	\$92.00
Claims Fee (2 extra)			

Notification Regarding Change in Status U.S.S.N. 08/737,457 Page 2 of 2

JUL 3 9 2004

Type of Fee	Fee Paid & Date Paid	Current Fee Amount	Deficiency
	(Small Entity Amount)	(Non-Small Entity)	(Amount Owed)
Multiple Independent Claim Fee	\$135.00 on May 25, 2001	\$290.00	\$155.00
One-month Extension of Time Fee	\$55.00 on May 25, 2001	\$110.00	\$55.00
One-month Extension of Time Fee	\$55.00 on August 13, 2001	\$110.00	\$55.00
Three-month Extension of Time Fee	\$460.00 on April 15, 2002	\$950.00	\$490.00
Petition for Revival of an Unintentionally Abandoned Application	\$665.00 on February 26, 2004	\$1,330.00	\$665.00
Total Deficiency			\$1955.00

Respectfully submitted,

Date: July 9, 2004 Reg. No.: 48,645

Tel. No. (617) 248-7697 Fax: (617) 248-7100

3090727

Brian A. Fairchild, Ph.D. Attorney for Applicants Testa, Hurwitz, & Thibeault

High Street Tower 125 High Street

Boston, Massachusetts 02110





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office; Address COMMESSIONER OF PATENTS AND TRADEMARK Washington and 2020.

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
08/737.457	03/12/1997	DONALD LEONARD NICHOLAS CARDY	960670. PR/C	5220
. 15	90 01/13/2003	:		
ORRIN M HA	UGEN	•	EXAMI	NER
HAUGEN AND 820 INTERNAT	NIKOLAI FIONAL CENTRE	more than the second	EWOLDT. C	GERALD R
	AVENUE SOUTH S, MN 554023325	100	ART UNIT	PAPER NUMBER
			[644	
	\mathcal{C}	>(())/\(\bar{\bar{\bar{\bar{\bar{\bar{\bar{	DATE MAILED: 01/13/2003	27
	110			N
	// '			

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office** COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER

FILING DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

EXAMINER					
ART UNIT	PAPER NUMBER				
	37				

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 -1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132. Specifically, the sequence in Figure 10 and in the seventh paragraph at page 8 of the specification must be brought into sequence compliance.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Christina Chan whose telephone number is (703) 308-3973. The fax number for the organization where this application is assigned is (703) 308-4242.

G.R. Ewoldt, Ph.D. Patent Examiner

Tech Center 1600 December 27, 2002

App can No.: 08/737,457

NOTICE TO COMPLY WITH TO QUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND TO MINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

2. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as re 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, content of the computer readable form does not comply with the requirements of 37 C.F.F. and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing" 5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing include include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212	5. Applicant's 1990), and 1114 final rulemaking
 □ 37 C.F.R. 1.821(e). □ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However content of the computer readable form does not comply with the requirements of 37 C.F.F. and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing" □ 5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). □ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from "Sequence Listing" as required by 37 C.F.R. 1.821(e). □ 7. Other: □ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". □ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direct into the specification. □ A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). □ For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216 	a "Sequence
content of the computer readable form does not comply with the requirements of 37 C.F.F. and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing" 5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direct into the specification. A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	as required by
and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direct into the specification. A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	C.F.R. 1.822
"Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direct into the specification. A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direct into the specification. A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	rom of the
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direct into the specification. A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direct into the specification. A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	
into the specification. A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	
applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216	directing its entry
For Rules Interpretation, call (703) 308-4216	
Patentln Software Program Support Technical Assistance	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



UNITED STAY, TENT AND TRADEMARK OFFICE





COMMISSIONER FOR PATER UNITED STATES PATENT AND TRADEMARK OFFICE P.O. Box 1450 ALEXANDRIA, VA 22313-1450

www.uspto.go

Paper No. 44

Orrin M. Haugen Haugen and Nikolai 820 International Centre 900 Second Avenue South Minneapolis, MN 55402-3325 **REC'D** APR 1 2 2004

COPY MAILED

APR 0 9 2004

OFFICE OF PETITIONS

In re Application of Cardy et al. Application No. 08/737,457 Filed: March 12, 1997 Attorney Docket No. 960670.CNC

ON PETITION

This is a decision on the petition under 37 CFR 1.137(b), filed March 1, 2004, to revive the above-identified application.

The petition is **DISMISSED**.

Any request for reconsideration of this decision must be submitted within TWO (2) MONTHS from the mail date of this decision. Extensions of time under 37 CFR 1.136(a) are permitted. The reconsideration request should include a cover letter entitled "Renewed Petition under 37.CFR 1.137(b)." This is not final agency action within the meaning of 5 U.S.C. § 704.

The above-identified application became abandoned for failure to reply in a timely manner in reply to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and /or Amino Acid Sequence Disclosures mailed January 13, 2003. The Notice set a period for reply of (30) Thirty Days from the mail date of the Notice. No extensions of time under the provisions of 37 CFR 1.136 have been obtained. Accordingly, the application became abandoned on February 14, 2003.

A grantable petition under 37 CFR 1.137(b) must be accompanied by: (1) the required reply, unless previously filed; (2) the petition fee as set forth in 37 CFR 1.17(m); (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional; and (4) any terminal disclaimer (and fee as set forth in 37 CFR 1.20(d)) required by 37 CFR 1.137(c). Where there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137 was unintentional, the Commissioner may require additional information. See MPEP 711.03(c)(III)(C) and (D). The instant petition lack(s) item(s) (1).

Item (1), The reply filed March 1, 2004 fails to comply with the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed January 13, 2003. Accordingly, this application cannot be revived until a complete reply has been submitted.

Further correspondence with respect to this matter should be addressed as follows:

By mail:

Mail Stop Petitions

Box DAC

Washington, D.C. 20231

By facsimile:

(703) 872-9306

Attn: Office of Petitions

By hand:

2201 South Clark Place

Crystal Plaza 2, Lobby

Room 1B03

Arlington, VA 22202

Telephone inquiries concerning this decision should be directed to Latrice Bond at (703) 308-6911.

Latrice Bond

Paralegal Specialist

Jatue Bon

Office of Petitions

Office of the Deputy Commissioner

for Patent Examination Policy